| In total | Fully agree (1) | partially agree (2) | neutral (3) | partially disagree (4) | fully disagree (5) | No answer |
---|---|---|---|---|---|---|---|
Moderate hypofractionated radiotherapy (regardless of focal dose escalation) will be the standard of care for the envisaged patient cohort in 10 ten years | 9 | 56% | 33% | 11% | 0% | 0% | 0% |
Patients in the envisaged cohort will not be treated with moderate hypofractionated radiotherapy in 10 years, since all parients will be treated with SBRT | 9 | 0% | 0% | 44% | 44% | 11% | 0% |
Patients in the envisaged cohort will not be treated with moderate hypofractionated radiotherapy in 10 years, since all parients will be treated with brachytherapy (at least for dose escalation purposes) | 9 | 11% | 0% | 0% | 33% | 56% | 0% |
Patients with cT3a stage should be excluded in the clinical trial | 9 | 0% | 0% | 22% | 11% | 67% | 0% |
Patients with cT3b stage should be excluded in the clinical trial | 9 | 33% | 11% | 22% | 11% | 22% | 0% |
Patients with gleason score 9 should be excluded in the clinical trial | 8 | 50% | 13% | 0% | 0% | 13% | 25% |
Duration of 6 months androgen deprivation therapy for unfavorable intermediate risk and 18 months for high risk patients is adequate | 8 | 13% | 13% | 50% | 0% | 13% | 13% |
Elective lymph nodes shold be treated in patients with cN0 stage according to PET and MRI but high risk of nodal disease | 7 | 0% | 29% | 29% | 0% | 43% | 0% |
Urethra should be delineated and spared | 8 | 50% | 13% | 38% | 0% | 0% | 0% |
The proposed dose concept (62 Gy to the whole prostate with focal boost up to 75 Gy in 20 fractions in the experimental arm) seems reasonable | 10% | 10% | 20% | 60% | 0% | 0% | 10% |